Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

K. Ramasamy · SciRah

Researcher profile · Semantic Scholar

K. Ramasamy

Share profile

K. Ramasamy — researcher profile on SciRah

h-index: 28
Works: 262
Citations: 3,004

Most-cited papers

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
N. Raje, K. Anderson, H. Einsele, Y. Efebera +9 more
2023Blood Cancer Journal194 citations Open access
Semantic Scholar
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
P. Richardson, S. Trudel, R. Popat, M. Mateos +27 more
2023New England Journal of Medicine70 citations Open access
Semantic Scholar
Clinical features and diagnosis of multiple myeloma: a population-based cohort study in primary care
A. Seesaghur, Natalia Petruski-Ivleva, V. Banks, J. Wang +3 more
2021BMJ Open34 citations Open access
Semantic Scholar
Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial
P. Richardson, S. Trudel, H. Quach, R. Popat +15 more
2022Blood21 citations Open access
Semantic Scholar
Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma
S. Gooding, N. Ansari-Pour, Mohammad H. Kazeroun, K. Karagoz +14 more
2022Blood21 citations Open access
Semantic Scholar
MGP Panel is a comprehensive targeted genomics panel for molecular profiling of multiple myeloma patients
Parvathi Sudha, Aarif Ahsan, C. Ashby, T. Kausar +21 more
2022Clinical Cancer Research20 citations Open access
Semantic Scholar
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
K. Kurata, Anna James-Bott, M. Tye, Leona Yamamoto +25 more
2023Blood Cancer Journal19 citations Open access
Semantic Scholar
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial
M. Dimopoulos, F. Schjesvold, V. Doronin, O. Vinogradova +16 more
2022Blood Cancer Journal19 citations Open access
Semantic Scholar
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial
Kara-Louise Royle, A. Coulson, K. Ramasamy, D. Cairns +25 more
2022BMJ Open17 citations Open access
Semantic Scholar
COVID symptoms, testing, shielding impact on patient‐reported outcomes and early vaccine responses in individuals with multiple myeloma
K. Ramasamy, R. Sadler, Sally Jeans, Sherin Varghese +14 more
2021medRxiv15 citations Open access
Semantic Scholar
Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial
Luciano J. Costa, F. Schjesvold, R. Popat, David S. Siegel +19 more
2024Blood13 citations
Semantic Scholar
Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis
S. Usmani, Michał Mielnik, M. Garg, I. Sandhu +16 more
2024Blood12 citations
Semantic Scholar
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.
K. Yong, W. Wilson, R. de Tute, M. Camilleri +17 more
2022The Lancet Haematology12 citations Open access
Semantic Scholar
Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset
F. Djebbari, Alexandros Rampotas, G. Vallance, F. Panitsas +24 more
2022HemaSphere11 citations Open access
Semantic Scholar
The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease
P. Richardson, M. Mateos, A. Vangsted, K. Ramasamy +4 more
2022Espert Review of Proteomics11 citations
Semantic Scholar
Monoclonal gammopathy of increasing significance: time to screen?
Lucia Y. Chen, M. Drayson, C. Bunce, K. Ramasamy
2022Haematologica10 citations Open access
Semantic Scholar
Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry.
Hans C. Lee, K. Ramasamy, K. Weisel, R. Abonour +16 more
2022Clinical Lymphoma, Myeloma & Leukemia10 citations Open access
Semantic Scholar
Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study
A. Nooka, T. Cochrane, Anita D'Souza, J. Matous +13 more
2024Blood9 citations
Semantic Scholar
Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients
F. Djebbari, Alexandros Rampotas, F. Panitsas, W. Lim +14 more
2022PLoS ONE9 citations Open access
Semantic Scholar
A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9.
S. Usmani, Michał Mielnik, J. Byun, A. Alonso +16 more
2023Journal of Clinical Oncology8 citations Open access
Semantic Scholar
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series
F. Djebbari, M. Poynton, G. Sangha, Laura Anderson +5 more
2022Hematology8 citations Open access
Semantic Scholar
Dysregulated immune proteins in plasma in the UK Biobank predict multiple myeloma 12 years before clinical diagnosis
J. Fieggen, A. Thakur, Christopher C. Butler, K. Ramasamy +3 more
2025medRxiv7 citations Open access
Semantic Scholar
A UK consensus algorithm for early treatment modification in newly diagnosed systemic light‐chain amyloidosis
S. Ravichandran, S. Mahmood, B. Wisniowski, S. Sachchithanantham +12 more
2022British Journal of Haematology7 citations
Semantic Scholar
Immune response to COVID‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response
K. Ramasamy, R. Sadler, Sally Jeans, Paul Weeden +16 more
2022British Journal of Haematology7 citations Open access
Semantic Scholar
Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort
N. Maouche, B. Kishore, Zara Bhatti, Supratik Basu +10 more
2022PLoS ONE7 citations Open access
Semantic Scholar
Sustained Improvement in Health‐Related Quality of Life in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient‐Reported Outcomes
A. Perrot, T. Facon, T. Plesner, S. Usmani +22 more
2025European Journal of Haematology6 citations Open access
Semantic Scholar
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.
X. Leleu, Hans C. Lee, J. Zonder, M. Macro +9 more
2024Future Oncology6 citations Open access
Semantic Scholar
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
K. Ramasamy, H. Avet-Loiseau, Cecilie Hveding Blimark, M. Delforge +7 more
2023HemaSphere6 citations Open access
Semantic Scholar
Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) - Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation
K. Yong, Kara-Louise Royle, K. Ramasamy, C. Parrish +22 more
2022Blood6 citations Open access
Semantic Scholar
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study
F. Djebbari, Alexandros Rampotas, G. Vallance, F. Panitsas +25 more
2022Hematology6 citations Open access
Semantic Scholar
Patient-reported symptoms and diagnostic journey in Multiple Myeloma
R. Vijjhalwar, Kai-Yang Song, Roshi Shrestha, S. Bowcock +3 more
2023Frontiers in Oncology5 citations Open access
Semantic Scholar
Real‐world treatment patterns in patients initiating third‐line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain
M. Lehne, K. Kortüm, K. Ramasamy, E. Zamagni +9 more
2023European Journal of Haematology5 citations Open access
Semantic Scholar
Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma
Carmen Tsang, Joseph E. O’Reilly, Lewis Carpenter, C. Duffield +6 more
2025BMC Cancer4 citations Open access
Semantic Scholar
Inhibition of PI3K Class IA Kinases Using GDC-0941 Overcomes Cytoprotection of Multiple Myeloma Cells in the Osteoclastic Bone Marrow Microenvironment Enhancing the Efficacy of Current Clinical Therapeutics
H. Kikuchi, Eunice Amofa, M. Mcenery, S. Schey +3 more
2023Cancers4 citations Open access
Semantic Scholar
Elranatamab for relapsed/refractory multiple myeloma – multi-centre real-world outcomes from the United Kingdom
O. Tomkins, Hannah Giles, Guy Pratt, B. Kishore +28 more
2025Blood3 citations
Semantic Scholar
RADAR Trial: MRD Response Adapted Trial for Newly Diagnosed Transplant Eligible Myeloma Patients
K. Ramasamy, D. Cairns, Kara-Louise Royle, Robert Cicero +24 more
2023Blood3 citations Open access
Semantic Scholar
BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events
E. Watson, F. Djebbari, Alexandros Rampotas, K. Ramasamy
2022Expert Review of Hematology3 citations
Semantic Scholar
Belantamab Mafodotin Monotherapy for Multiply‐Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of Ireland
Edmund C R Watson, F. Djebbari, F. Panitsas, G. Vallance +23 more
2025eJHaem2 citations Open access
Semantic Scholar
Castleman disease
J. Qasim, K. Ramasamy
2025Rheumatology2 citations Open access
Semantic Scholar
Impact of renal impairment (RI) on pharmacokinetics (PK) and clinical outcomes with mezigdomide plus dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM).
S. Trudel, Nizar J. Bahlis, R. Popat, María-Victoria Mateos +15 more
2024Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Development of a Spatial Multiomics Platform to Integrate Genomic, Transcriptomic and Proteomic Features for Translational Research in Multiple Myeloma
S. Gooding, Chen-Yi Wang, Warren Baker, E. Watson +15 more
2024Blood2 citations
Semantic Scholar
Secure: A Prospective Long-Term Observational Study in Patients with Monoclonal Gammopathy of Undetermined Significance
K. Ramasamy, Elizabeth Knight, Sulgi Byun, E. Heartin +36 more
2024Blood2 citations
Semantic Scholar
High Success Rates Utilizing Local Standard of Care Cytogenetic Testing for Risk Stratified Frontline Therapy for Newly Diagnosed Multiple Myeloma: Experience from the Ukmra RADAR Study
Dipal Mehta, L. Chiecchio, Martin F. Kaiser, S. Gooding +26 more
2023Blood2 citations Open access
Semantic Scholar
Editorial: T-cell directed therapies in multiple myeloma
J. Richter, L. Anderson, K. Ramasamy, A. Rossi
2023Frontiers in Oncology2 citations Open access
Semantic Scholar
P945: REAL-WORLD CLINICAL OUTCOMES AMONG TRIPLE-CLASS EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS IN US AND EUROPE: A PREAMBLE REGISTRY STUDY
K. Ramasamy, H. Goldschmidt, P. Moreau, Maria Teresa Petrucci +10 more
2023HemaSphere2 citations Open access
Semantic Scholar
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
K. Kurata, Anna James-Bott, M. Tye, Leona Yamamoto +25 more
2023Blood Cancer Journal2 citations Open access
Semantic Scholar
Network Meta-Analysis of Randomized Trials in Relapsed/Refractory Multiple Myeloma: Relative Efficacy for Patients Who Are Lenalidomide-Refractory
E. Kastritis, R. Harvey, Holly Cranmer, Martina Bianco +3 more
2023Blood2 citations Open access
Semantic Scholar
Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial
K. Ramasamy, G. Iqbal, Richard Brouwer, Victoria Stalker +6 more
2022Blood Cancer Journal2 citations Open access
Semantic Scholar
Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias Using DW-MRI and Exploratory Bone Biomarkers
G. Agarwal, G. Nador, Sherin Varghese, Hiwot Getu +18 more
2022Cancers2 citations Open access
Semantic Scholar
Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study
Saad Z. Usmani, Michał Mielnik, Aránzazu Alonso Alonso, Al-Ola A. Abdallah +18 more
2025Blood1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Popat×11
Invite
R. Popat — researcher profile on SciRah
H. Quach×9
Invite
H. Quach — researcher profile on SciRah
S. Gooding×9
Invite
S. Gooding — researcher profile on SciRah
C. Bygrave×9
Invite
C. Bygrave — researcher profile on SciRah

×8

Invite

M. Drayson — researcher profile on SciRah

Invite

K. Yong — researcher profile on SciRah

Invite

A. Thakurta — researcher profile on SciRah

Supratik Basu×6

Invite

Supratik Basu — researcher profile on SciRah

Invite

K. Weisel — researcher profile on SciRah

Invite

F. Djebbari — researcher profile on SciRah

Invite

G. Vallance — researcher profile on SciRah

Invite

M. Mateos — researcher profile on SciRah